![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CALLISTO PHARMACEUTICALS GRANTED ORPHAN DRUG DESIGNATION FOR ANNAMYCIN TO TREAT ACUTE LYMPHOBLASTIC LEUKEMIA
CALLISTO PHARMACEUTICALS GRANTED ORPHAN DRUG DESIGNATION FOR ANNAMYCIN TO TREAT ACUTE LYMPHOBLASTIC LEUKEMIA
June 28, 2005
Callisto has announced that the Office of Orphan Products Development of the FDA has granted orphan drug designation to the company's drug candidate Annamycin for the treatment of acute lymphoblastic leukemia.
Annamycin, a second-generation anthracycline developed at M.D. Anderson Cancer Center, is being developed by Callisto to treat relapsed acute leukemia patients.
Callisto plans to begin a clinical trial in adult relapsed acute lymphoblastic leukemia patients in the near future.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct